An Exploratory Study to Evaluate Skin Brightening Effects of Different Cosmetic Formulations on UV Irradiated Tanning Model
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Sunny Du
- Telefonnummer: +86 21 22128000
- E-Mail: Sunny.Du@unilever.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Healthy Chinese female or male, aged from 18 to 50 years old (both inclusive).
- Participants in good health condition as per the health history questionnaire with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data.
- Participant is able to read, understand and sign an appropriate informed consent form indicating his willingness to participate.
- ITA° range 10-42°; Skin type III and IV included and can tolerance 2MED radiation.
- No history of allergic diseases or allergies to cosmetics, UV light and other topical preparations.
- No history of photosensitive diseases and no recent use of medications that affect photosensitivity.
- The test area skin (back) should be free of birthmarks, inflammation, scars, excessive hair, etc.
- No cuts, abrasions, fissures, wounds, lacerations on the test site (back).
- Participants must understand the trial process, voluntarily participate in the study, and sign a written informed consent form.
- Willing to attend the study center twice daily for product application during the study period and complete all visits.
Exclusion Criteria:
- Study participants are employees of Sponsor or CRO.
- The study participants participated in test involving the test site within 2 months prior to the start of this test or are currently participating in such tests.
- Study participants had any other visible signs of local irritation, erythema, or skin disease on the visible parts of the body.
- Study participants consider they are prone to breakouts and/or sensitive skin.
- Study participants had a chronic illness or had major surgery in the past year.
- Study participants were receiving any skin treatments on the test sites.
- Study participants had allergies or sensitivities to cleansing products, creams/emulsion, costume jewelry, or other things.
- Female study participants were pregnant/breastfeeding or planning to become pregnant during the trial (study participants self-declared at screening visits).
- Study participants took medication for any condition, which the researchers believe may have affected the interpretation of the data.
- Study participants had a history of psoriasis, eczema, atopic dermatitis, severe acne, etc. Or have other chronic systemic diseases.
- Study participants had received oral or topical corticosteroids and other anti-inflammatory drugs within the last 1 month.
- Study participants used tartaric acid, salicylic acid and any other products or drugs that affect skin colour (such as hydroquinones) within the last 2 months.
- Study participants used retinoic acid preparations or aesthetic treatment such as chemical stripping, laser, pulsed light, etc. in the test site in the past three months.
- Study participants were inevitably exposed to prolonged sunlight.
- Clinical evaluation considers that participants are not suitable for the test.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Kein Eingriff: Unbehandelt
|
|
|
Placebo-Komparator: SMR 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Placebo-Komparator: Pro-Derma 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Aktiver Komparator: Thiamidol
|
Cosmetic skin brightening product to be applied to defined test site
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
L*, a*, b*, ITA
Zeitfenster: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin color (L*, a*, b* values, calculate ITA°) on the back test areas using Spectrophotometer, CM-26d.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Hydration and barrier function
Zeitfenster: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin hydration on the back test areas using Corneometer, CM825.
Measure TEWL on the back test areas using Vapometer .
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Image demo
Zeitfenster: From 1-week pre-treatment phase to end of study at 8 weeks
|
Capture images on the back test areas using Antera 3D device.
Capture images on the back test areas using digital camera.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- SKN-MDV-4589
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .